Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders
Key facts
- Who runs it
- Henry Ford Health System
- Where
- Detroit, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 15 people enrolled
- Started
- 26 Feb 2016
- Ended
- 1 Apr 2025
- Type of study
- Interventional
- Treatments tested
- Standard of care chemotherapy with the change for avoidance of extensive surgery
- Record updated
- 23 July 2026
- Why it stopped
- Lack of financial support
Who can take part
- Age
- 18 years to 95 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥ 18 years
- Diagnosis of rectal invasive adenocarcinoma
- Tumor in the low or mid rectum (up to 11 cm from the anal verge)
- Clinical stage T3/N0-N1M0. Patients with low T2 who will need abdominal perineal resection are also eligible
- Clinical staging will be estimated based on the combination of the following assessments:
- Physical examination by the primary surgeon
- Computed Tomography or Positron Emission Tomography/Computed Tomography scan of chest, abdomen and pelvis
- Pelvic MRI and endoscopic ultrasound
Who cannot take part
- Less than 18 years of age
- Do not complete informed consent
- Pregnant women
Where in United States
- Ascension St. John HospitalDetroit, United States
About the trial
What the trial wants to find out
The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.
The group in the trial
- Neoadjuvant Chemotherapy and Follow-up SurgeryOther group
All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.
Treatment: Standard of care chemotherapy with the change for avoidance of extensive surgery
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (5FU/Capecitabine)-Radio Therapy (CRT) With Transanal Local Excision for Complete Responders
- Record updated
- 23 July 2026